Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-61
By Simon A. Jones. Journal of Immunology, 2005
824 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/7424e48f14bcda89b81b96d8ec6ee311d5f276c2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- S. Rose‐John
- J. Scheller
- Simon A. Jones
- J. Hidalgo
- Albert Quintana
- María Erta
- Luigi Ferrucci
- M. Karin
In Oncology
Citations in the corpus
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. (2011, background): “5, 31, 52, 63.”
- Interleukin‐6 biology is coordinated by membrane‐bound and soluble receptors: role in inflammation and cancer (2006, background): “A common feature arising amongst all of these studies is the role IL-6 trans-signaling performs in orchestrating leukocyte recruitment, activation, and apoptotic clearance [57].”
- Inflammation and Pregnancy (2006, background): “In several pathological conditions, elevated expression of MCP-1 advances the transition from acute to chronic infiltration by enhancing monocyte chemoattracton and activation.(72) However, accumulation of neutrophils in the decidua of abruption specimens is not accompanied by a change in macrophage”
- Interleukin-6 in aging and chronic disease: a magnificent pathway. (2006, background): “In addition, IL-6 confines neutrophil recruitment, favoring their replacement by mononuclear cells (41).”
- Research Progress on the Relationship between Atherosclerosis and Inflammation (2018, background): “Interleukin-6 is a pleiotropic cytokine and involves innate and adaptive immunity system and serves to regulate the acute-phase response and chronic inflammation [25].”
- Interleukin-6, a Major Cytokine in the Central Nervous System (2012, background): “The relevance of trans-signaling in vivo in a number of peripheral and CNS diseases is widely recognized [111, 149, 230-234], and not surprisingly therapeutic approaches aiming to counteract IL-6 effects not only focus in IL-6 membrane receptor [235-238] but also in IL-6/sIL-6R complex [13, 239-241]”